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ABSTRACT
Background. Depression is more prevalent 
in persons with chronic illnesses such as diabetes, 
epilepsy and infection of Human Immunodeficiency 
Virus (HIV). Depression can make HIV even. 
Antidepressant may be needed,  interaction and side 
effect may occur when using Antiretroviral (ARV) 
and antidepressant in combination. Complementary 
and alternative medicine (CAM) include Latihan 
Pasrah Diri(LPD) may seem safe to treat depression 
in HIV patients.
Methods. This is a quasi experimental 
study, participant include outpatient dan inpatient at 
RSUP Dr. Sardjito, Yogyakarta. They were aged >18 
years. After scoring with Zung Self Rating Scale for 
depression, participants allocated into two groups, 
with dan without Latihan Pasrah Diri program. 
Zung Self Rating Scale for depression was evaluated 
after 1 cycle of program.
Result. The means of Zung Self-Rating 
Depression Scale score before and after LPD were 
42,21 ± 9,3 and 35 ± 10,73 (p 0,003). While in 
control group (without LPD / brief psychotherapy) 
the means of Zung Self-Rating Depression Scale 
score before and 3 weeks after brief psychotherapy 
were 42,93 ± 7.45 and 39,36 ± 7,69 (p 0,019). 
Statistically there was no significancy in the means 
of delta Zung Self-Rating Depression Scale in LPD 
group and control group.
Conclusion. It was concluded from this 
study that there is an influence on the improvement 
of depressive symptoms post- Latihan Pasrah Diri 
program to people with HIV / AIDS.
Key words: depression, HIV, Latihan Pasrah Diri, 
Zung Self-Rating Scale
INTRODUCTION
Depression is more common in people with 
chronic diseases such as diabetes and epilepsy and 
post live events related to stress such as loss of 
1friends, parents and family . Depression in HIV / 
AIDS can be used to predict the acceleration 
decreased levels of lymphocyte Cluster of 
2Differentiation 4 (CD4) in HIV patients . 
Depression can affect the function of killer 
lymphocytes in HIV patients, and suspected 
depression causes increased activation of CD8 + and 
3viral load .
Depression that occurs in people with HIV 
and other conditions can aggravate the clinical 
patients. This happens because depression will 
cause a patient tends not to adhere to schedule 
consultations, not adhere to therapeutic dose, drug 
abuse and alcohol, eat irregularly, eat unhealthy food 
and withdraw from relationships and social 
4activities .
Treatment consist of pharmacotherapy and 
psychotherapy. Existing studies prove that 
psychotherapy gives similar clinical response 
compared to medication, so that one of two things 
can be justified empirically based physician and 
1patient preference . 
Meditation for medicinal purposes is a 
practice that includes body and soul and classified as 
a complementary and alternative medicine (CAM). 
There are several types of meditation, generally 
from religious and spiritual traditions use certain 
techniques such as focusing attention on a word, 
object, or breathing, with a specific posture and 
5being open to divert the mind and emotion .
The Mindfulness meditation and stress 
reduction programs to prevent the decline of CD4 + 
6T lymphocytes in adults infected individuals HIV-1 . 
Depression in people with HIV, 35.2% was treated 
7with relaxation and spiritual approach . In fact only 
few clinical evidences to recommend methods of 
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relaxation and spiritual approach to improve 
depression syndrome in patients with HIV, so this is 
very interesting to study to become a clinical footing 
or alternative treatment modalities of depression in 
people with HIV / AIDS. Latihan Pasrah Diri was 
an example of relaxation and spiritual approach that 
easily adapted, less expensive compared to other 
method of relaxation or spiritual approach.
METHOD
Research Subjects
Subjects were HIV / AIDS patients who 
experienced symptoms of depression, hospitalized 
in internal medicine wards Dr. Sardjito General 
Hospital, and maintained in the outpatient clinic of 
psychosomatic and edelweiss Dr. Sardjito 
Yogyakarta. Inclusion criteria for research subjects: 
aged> 18 years, signed informed consent, had tested 
positive for HIV / AIDS, showed symptoms of 
depression. Exclusion criteria: not suffering from 
kidney failure, chronic heart failure, stroke, diabetes 
mellitus, bronchial asthma, COPD, cancer, and 
epilepsy.
Research Design
The research was conducted with the design 
quasi experimental study. Research subjects who 
fulfilled the inclusion criteria were divided into two 
groups each of 32 people without randomization. 
One group was given Latihan Pasrah Diri program 
to one cycle (21 days) and the other group acted as 
control. Both Latihan Pasrah Diri and control groups 
were measured depression status using a 
questionnaire rating symptoms of  Zung Self-Rating 
Scale (Self-Assessment Scale) depression at 
8.9baseline and after the program is completed .
Latihan Pasrah Diri (LPD) is a training 
given twice a day for 21 consecutive days. This 
training is the combination of relaxation with mental 
dzikir [carry the Quran s. al-A'raf (7): 205 and al-
Ahzab (33): 41] and control of regulate breath of 16-
20 times per minute, which performed in the 
8morning and afternoon . 
Measurement
Assessment of depressive symptoms using 
a questionnaire Zung Self-Rating Scale (Self-
Assessment Scale) had been already validated in 
Indonesian language. The maximum value of this 
questionnaire is 80, and the patient is categorized as 
having symptoms of depression when the obtained 
9value > 40 . Determination of the status of HIV / 
AIDS carried out by examination with anti-HIV 
10ELISA method .
Hypotheses and Statistical Analysis
The hypothesis of this research is the 
improvement of depression symptoms post-Latihan 
Pasrah Diri program to people with HIV / AIDS. 
Data characteristics of study subjects are presented 
in the mean number and percentage. Normal 
distribution of variables is determined by Shapiro-
Wilk test. To determine differences in mean score of 
Zung Self-Rating Scale (Self-Assessment Scale) 
depression in the group treated with the group 
without treatment used Indepenent t-test. To 
determine differences in mean score of Zung Self-
Rating Scale (Self-Assessment Scale) depression in 
groups with LPD and without LPD were compared 
between the beginning and end of the study used  
Paired t-test. Difference of mean score of Zung Self-
Rating Scale depression (Self-Assessment Scale), 
between smoking and nonsmoking groups at the end 
of the study in groups LPD and without LPD used 
independent t-test. Statistically significant 
differences determined by the value of P <0.05 and 
confidence interval (CI) 95%. 
RESULT
The study was conducted in October and 
November 2010. Basic characteristics of study  
subjects are shown in table 1. The total sample in the 
treatment group where 16 people, but 2 people (1 
male and 1 female) were lost to follow-up, 1 person 
declined to be evaluated after 1 cycle of LPD and 1 
person could not be contacted, in the control group, 
initially there were 15 persons but 1 person (Male) 
was eventually not willing to participate in the 
evaluation.
The mean age in this study is younger than 
previous studies, ie 27.4 years in the treatment group 
and 29.8 years in the control group. Age of HIV 
patients with depression in a study by Lyketsos et al. 
11is 33.2 years old . Older age reported for HIV group 
was 35.2 +5.8 years and 36.2 +6.0 with depression in 
2the HIV group with affective depression . Creswell 
6et al. reported an older age of 40 . Age on the 
research findings are consistent with national data 
where most AIDS patients aged 20-29 years later 
12followed by 30-39 years (MOH, 2009) .
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Table 1. Basic Characteristics of Study Subjects
Poupard et al. states that 18% of the use of 
efavirenz-based antiretroviral experienced 
13depression . Ribs et al. stated 19% of patients 
receiving efavirenz experienced severe to very 
severe stress compared with not getting efavirenz (p 
14= 0.014) .
Clifford et al. reported that the patients often 
complained of subjective neurologic effects on the 
use of efavirenz, but generally not severe and the 
patient remains safe to continue the use of drugs and 
15the symptoms will soon disappear .
At the beginning of the study, both groups 
showed a mean score of Zung Self-Rating Scale 
depression more than 40 which means that in both 
groups experiencing symptoms of depression. At the 
end of the study, Zung Self-Rating Scale of the both 
groups was significantly depressed, as seen in table 
2.
Table 2. Comparison of the mean score of 
Zung Self-Rating Depression Scale at the 
beginning and end of the study
#paired t-test
Characteristics
 
LPD(%)(n=14) Without LPD(%)(n=14)
Age
 
Sex
 
Male
 
Female
 
Education
 
SD
 
SMP
 
SMA
 
D3
 
S1
S2
Risk factor
NAPZA
Non NAPZA
ART
In therapy
With Evarirenz 
Smoking history
smoking
Non smoking
27,4
2(14,3)
12(85,7)
2(14,3)
3(21,4)
7(50)
2(14,3)
3(21,4)
11(78,6)
11(78,6)
4(28,6)
7(50)
7(50)
29,8
10(71,4)
4(28,6)
1(7,1)
2(14,3)
8(57,1)
2(14,3)
1(7,1)
6(42,9)
8(57,1)
14(100)
8(57,1)
10(71,4)
4(28,6)
Variabel baseline End of study P
LPD (n=14)
 
42,2+9,25 35+10,72 0,003#
 
Without  LPD 
(n=14)
 42,9+7,49 39,6+7,68 0,019#
Decrease in the mean score Zung Self-
Rating Depression Scale in the LPD group was 
significant. Although a significant decrease was also 
observed in the group without LPD, but a greater 
decrease was shown in score on the LPD group. This 
shows the benefits of LPD as a treatment modality 
of depression in people with HIV / AIDS.
Oman et al. found that subjects who 
received therapy Mindfulness-based stress 
reduction (MBSR) after 8 weeks on the program 
showed significant benefits in reducing stress (P 
17<0.05) . Studies on the benefits of transcendental 
meditation for reducing depression are also shown 
in studies conducted at Charles Drew University in 
Los Angeles and University of Hawaii at Kohala, 
including African American and Native Hawaiian, 
55 years and older, the risk of cardiovascular 
disease. Participants in both studies who practice the 
Transcendental Meditation program showed 
significant reductions in symptoms of depression 
compared with controls. The most significant 
decrease was found in participants who have 
indicated a significant clinical depression, and those 
who practiced the Transcendental Meditation show 
an average reduction in depression symptoms by 
1848% .
Woolery et al. showed a decrease in 
depression scores at the end of the study compared 
to baseline in the yoga group than in controls (P 
<0.001). This randomized study showed that 
practicing yoga could provide therapeutic benefit in 
mild depression, reduce anxiety, improve feelings 
19and affects the work kortisol .
Although there is improvement of 
symptoms of depression based on scores decreased 
Zung Self-Rating Depression Scale LPD group, but 
the decline was also observed in the group without 
LPD. The most reasonable explanation to show the 
explicit decrease in the score of the group without 
LPD was the fact that at the beginning of the study, 
both group with LPD or without LPD were given 
short psychotherapy (brief psychotherapy) to raise 
their enthusiasm, motovation and positive thinking 
in facing their illnes. The other reason that may 
cause the explicit decrease in the score that 
encouraged the patients to be more obedient to their 
therapy and pay more attention to the things that 
could affect their health was the information that 
there would be an evaluation given at the end of the 
study.
At the beginning of the study both groups of 
LPD and without LPD showed depressive 
symptoms (score of Zung Self-Rating Depression 
Scale> 40), and at the end of the study both group 
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Table 3. Comparison of the delta score of 
Zung Self-Rating Depression Scale between 
the groups with LPD and without LPD
*Independent t-test
The results of previous studies and the 
results of this study provide clinical evidence that 
meditation, yoga or any exercise for Latihan Pasrah 
Diri can improve depression symptoms in people 
with HIV / AIDS. 
Limitations of this study are: First, the 
research subjects who can not follow the evaluation 
at the end of the study (lost to follow-up) either in the 
LPD group and the group without LPD. Second, the 
small sample size. A larger sample size would 
certainly add the strength of this research. Third, a 
quasi experimental research design to ensure 
implementation of the LPD did not really fit the 
guidelines. Fourth, factors that may affect the 
depression such as the use of antiretroviral drugs 
and antidepressants can not be controlled. 
CONCLUSION
In conclusion there is an influence on the 
improvement of depressive symptoms post-
Exercise Latihan Pasrah Diri on HIV / AIDS. We 
suggest a research design should be selected 
randomized controlled clinical trials with larger 
sample size. Randomized controlled clinical trials 
can be done by dividing the study subjects by simple 
random allocation.
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ABSTRACT
Acute pulmonary embolisms is a major 
cause of complications and death associated in 
surgery, medical illnesses, injury, and also may 
occurs after  a long-distance air travel. It is often 
originating from deep-vein thrombosis and has a 
wide spectrum of clinical manifestation ranging 
from asymptomatic, incidentally discovered emboli, 
to massive embolism causing immediate death. 
Incidence of pulmonary embolism ranges from 23-
69 cases per 100,000 populations. Case fatality 
rates vary widely depending on the severity of the 
cases; at an average case fatality rate within 2 week 
of diagnosis of approximately 11%. It may have 
chronic sequele as post thrombotic syndrome and 
chronic thromboembolism pulmonary hypertension.
Acute pulmonary embolism is often difficult 
to diagnose. The predisposing factors for pulmonary 
embolisms consist of hereditary factors, acquired 
factors, and probable factors. Patients with 
symptoms of dyspnea, chest apnea, tachypnea or 
tachycardia arise suspiciousness of pulmonary 
embolisms therefore should be screened their 
probability for developing the disease. Low risk 
patients will then be evaluated for d-dimer test. 
Treatment should be initiated promptly in high risk 
patients, followed by imaging procedure evaluation. 
Chest radiographs, CT scan arteriography, VQ scan 
are performed to either include or exclude diagnosis 
of pulmonary embolisms.
Treatments consist of thrombolysis for acute 
and unstable massive pulmonary embolisms, and 
anticoagulation with heparin for stable acute 
pulmonary embolism. A meta-analysis of several 
major trials showed that low molecular weight 
heparin is at least as effective as unfractionated 
heparin in preventing the recurrence of venous 
thromboembolism events and at least as safe with 
respect to the rate of major bleeding.
This review will further describe in detail 
the pathomechanisms, diagnosis, and management 
of acute pulmonary embolisms.
INTRODUCTION
Pulmonary  embol isms (PE)  i s  a  
cardiovascular and cardiopulmonary symptoms 
caused by oclusion of the main pulmonary vessels 
by embolic process. Embolism is originated from 
detachment of thrombus – ussually from deep vein 
1,2  thrombosis- and then propagated . Pulmonary 
embolisms (PE) and deep vein thrombosis (DVT) is 
one spectrum of disease. About 79% of patients with 
PE have DVT in their legs and 50 % of patients with 
3DVT will progress to PE .
In US incidence of PE reaches 1 per 1000 
population; with 15 % mortality within 3 month of 
diagnosis. Mortality due to PE reaches 300,000 
cases per year that make it as deadly as acute 
3coronory syndrome . 
Eventhough in some certain countries 
incidence of venous thromboembolisms is not  
frequent, awareness of it should be routinely 
performed especially for highrisk groups of patients 
4.
Diagnosing PE is not easy. Lack of 
awareness and non specific symptoms and signs of 
PE make it difficult to diagnose at early course of 
disease and many of  PE are diagnosed post 
mortemly.
This review is aimed at describing clinical 
manifestations of pulmonary embolisms, its 
pathomechanisms, diagnostic procedures, and 
management based on the most recent literatures and 
publications.
Pathophysiology
Thrombi arises from deep veins in the lower 
extremity, propagate in the proximal veins include 
popliteal veins and their upper veins, in which is 
3easier to form embolization . Emboli migrates from 
right ventricle and plugs pulmonary arterial.  
In acute PE, anatomical obstruction will 
decrease pulmonary function, followed by secretion 
of vasoactive and bronchoactive mediators that lead 
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to impairment of ventilation-perfusion. Increasing 
of right ventricle wall pressure cause ventricle 
dilatation, dysfunction, and ischemic of right 
ventricle. Death may caused by right ventricular 
3failure .
Risk Factors
Many health's condition and genetic factors 
increase the risk of PE. All risk factors of DVT 
become risk factors of PE. Table 1  gives summary 
of the risk factors of PE including hereditary and 
acquired risk factors.
Acquired
 
Genetic Possible
immobiliza
tion
 
polycytemi
a
 
vera
 
Antithrombin
e deficiency
Increase of 
lipoprotein (a)
elderly
 
anti 
phospholi
pid 
syndrome
 
Protein C 
deficiency
Lack of Tissue 
Factor Inhibitor 
pathway
cancer
 
Oral 
contracept
ion
 
protein S
deficiency
Hyperhomocystei
nemia
Acute 
illness
 
Hormon 
replaceme
nt
Factor V 
Leiden
mutation
Increase factor
VIII
trauma heparin Resistant to 
active protein 
C
Increase of factor 
IX
Major 
surgery
chemother
apy
Mutation of 
prothrombin 
gene
Increase of factor 
IX
Spinal 
injury
Obesity dysfibrinogen
emia
Increase of 
fibrinolysis 
inhibitor
pregnancy Central 
vein 
catheter
Plasminogen
deficiency
Poost 
partum
cast and
immobilizer
Table 1. Risk Factors of Venous 
Thromboembolisms (Deep Vein Thrombosis 
3,5and Pulmonary Embolisms)
Diagnosis approach
Symptoms of PE are not specific. Dyspneu, 
tachycardia, pleuritic pain, and hemoptysis are 
sometimes found in patients with PE as well as other 
diseases. Cough, palpitation, light headedness, 
fever, and rales are common symptoms and signs 
which may be obscured by presenting  comorbid 
illness. Symptoms and signs of pulmonary 
hypertension like elevation of jugular vein pressure, 
loud P2, gallops on the right ventricle, and elevation 
of right heart configuration may rise suspicion to PE 
b u t  n e i t h e r   s e n s i t i v e  n o r  s p e c i f i c .  
Electrocardiography showed unexplained sinus 
tachycardia, and S1Q3T3 pattern in massive 
pulmonary embolisms, right bundle branch block, P 
pulmonale, and right axis deviation.  
Patient with PE usually present with 
hypoxemia, but somehow blood gas analysis 
showed normal results in large number of patients. 
Cyanosis, hypotension, and syncope may preceed a 
2,6,7  fatal and massive PE that lead to death . Troponin 
may increase in PE but should not be used as 
diagnosis marker; its indication is recommended for 
8prognostic stratification .
Upon suspicion of PE, physician should 
perform a comprehensive and detailed anamnesis, 
assessment of prediction probability of PE and its 
risk factors, biomarker test and diagnostic imaging. 
A  s i m p l e  m e t h o d  t o  p r e d i c t  
thromboembolism is developed by Wells et al using 
Clinical Prediction Rules for Pulmonary 
9,10,11Embolism . Beside Wells criteria, it has been 
developed other prediction criteria using more 
complicated items, radiographic imaging, and 
electrocardiography that should be interpreted by an 
1,5,12expert .
Tabel 2. Wells Clinical Prediction Rule 
9for Pulmonary Embolism (PE)
Clinical feature  PointsClinical symptoms of DVT
 
3
Other diagnosis less likely than PE 3
Heart rate greater than 100 beats per minute 1.5
Immobilization or surgery within past 4 weeks 1.5
Previous DVT or PE 1.5
Hemoptysis 1
Malignancy 1
Total points 12.5
Risk score interpretation (probability of PE):  
>6 points: high risk (78.4%);  
2 to 6 points: moderate risk (27.8%);  
<2 points: low risk (3.4%).
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Diagnostic Imaging
Patients with low probability of PE at 
outpatient setting should undergo D-Dimer test. D-
dimer is a method to measure degradation product of 
cross linked-fibrin in the blood circulation. This 
method has a high sensitivity value but low 
specificity. Increasing of D-dimer is  almost always 
happened in patients with emboli, as well as in 
elderly, trauma, post surgery, pregnancy, 
inflammation, and  cancer.  In patients with low risk 
probability and high D-Dimer results using highly 
sensitive D-Dimer assay should be followed by 
12imaging diagnostic procedures . In publication by 
Gibson et al D-Dimer test should be performed after 
clinical probability assessment or clinical prediction 
rule has done. High clinical probability patients 
should undergo other testing, regardless the D-
12,20Dimer outcome .
Treatment should be initiated promptly for 
high risk probability patients, while concommitantly 
carrying out diagnostic procedures such as helical 
CT scanning, ventilation-perfusion scanning, 
pulmonary arteriography until diagnosis is 
12established . Ventilation-perfusion scanning has the 
important role in diagnosing PE for almost 3 
decades. Positive results from ventilation-perfusion 
scanning (V/Q scanning) gives high sensitivity for 
thromboembolism. However many large trial 
showed patients with emboli showed normal 
12ventilation-perfusion scanning .
Computed Tomography scanning has 
superiority compared with ventilation-perfusion 
scanning in term of either sensitivity or specificity.  
Helical CT scan has 57-100% sensitivity and 78-
100% specificity. If the helical CT showed negative 
for PE, the likelihood of PE diagnosis is low, but can 
not directly exclude PE diagnosis as well as 
12ventilation perfusion scanning . A negative result of 
multidetector-row CT can safely rule out PE 
12,27diagnosis .
12Figure.1 Diagnostic approachs of pulmonary embolism
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Evaluation of veins in lower extremities should 
always be performed as PE arise from DVT. Duplex 
USG will be positive in 10-20% patients without 
symptoms in their leg, and USG of lower 
extremities' veins will positive in 50% patients with 
emboli. Normal USG duplex does not exclude 
12diagnosis of emboli .
Gold standard in PE diagnosis is pulmonary 
angiography. This invasive procedure needs 
specialistic technique and expert interpreter. 
Pulmonary angiography should be performed in 
condition where other non invasive diagnostic 
12procedures are not conclusive .
Treatment
Upon established diagnosis, patient with PE 
should be hospitalized and resting for the first 48 
3hours . If there were no contraindications, 
anticoagulation with heparin or low molecular 
weight heparin should be instituted. Survival will be 
improved with anticoagulation but recurrence rate is 
3still 5-10% within 1 year post diagnosis . Warfarin 
should be given concurrently with heparin at the first 
day of treatment.  Minimal duration of 
3anticoagulation is 5-days .Low molecular weight 
heparins have the similar efficacy as unfractionated 
heparin and have some advantages over it in term of: 
higher bioavailability, more predictable dose, 
heparin and have some advantages over it in term of: 
higher bioavailability, more predictable dose, 
convenient in usage, no need for monitoring, and 
f e w e r  i n c i d e n c e  o f  h e m o r r h a g e  a n d  
3,18,23thrombocytopenia .
Direct thrombin inhibitor is indicated for 
t h r o m b o o s i s  a n d  h e p a r i n - i n d u c e d  
th rombocytopenia .  Inh ib i to r  fac tor  Xa  
(rivuroxaban, apixaban, idraparinux and aptamers) 
3,15are still in phase 3 trial for PE .
Massive PE needs more aggresive 
treatment. Sodium chloride infusion, vasopressor, 
oxygenation, and intubation should be initiated in 
16cardiorespiratory failure .
Thrombolytic is indicated in PE presenting 
with cardiogenic shock, or systemic hypotension. In 
sub massive PE without shock thrombolytic 
treatment is still debatable. No significant difference 
between thrombolytic therapy and  heparinization in 
17PE, unless in severe and acute PE .
In massive, acute PE in which thrombolytic 
therapy is contraindicated, mechanical pulmonary 
3embolectomy should be performed .
1,23Table 3. Initial treatment for PE management
Drug  Mode of Administration
 
Note
Unfractionated heparin
 (intravenous infusion)
 
80U/kg
 
BW bolus iv 
continued with 18 IU/kg 
BW
 
/hours
 
continous 
infusion
 
Adjust the rate to achieve
aPTT 1.5 -2.5 times control 
monitor thrombocyte every 2 
days starting from day -4 up to 
da-14 or untill heparin is 
stopped. Aware of HIT if 
thrombocyte count decrease 
more than 50% OR developed 
thrombosis18
Low molecular weight heparin
 
(LMWH)
 
LMWH is not recommended 
for PE with hypotension or 
shock
          
enoxaparin
 
1.0 mg/kg
 
BW every 12 
hours sc or 1.5 mg/kg
 
BW once daily
If creatinin clearance <30 
ml/minute reduce dose to 
1 mg/kg BW/day or substitute 
with UFH
fondaparinux 5 mg for body weight < 
50 kg and 7.5 mg for 
body weight 50 kg-100 
kg and 10 mg for body 
weight > 100 kg
Contraindicated for creatinin
clearance < 30 ml
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Prognosis
Almost all patient with PE will survive after 
received adequate anticoagulation. Overall 
mortality rate within 3 months after  diagnosis is 15-
18%. Survival is determined by present or abscence 
of syncope or shock in the first hours of PE onset. 
Post  thrombotic syndrome and chronic 
thromboembolic pulmonary hypertension is a 
19,25common sequalae of PE .
Recurrency is still a major problem in acute 
PE. Recurrent VTE is found among 17.6% patients 
with symptomatic PE and among 9.5% patients  
DVT without symptomatic PE. Relative risk for 
recurrence VTE in PE is 2.2 (95% confident interval 
21  1.3-3.7,p=0.005) . Predictors of recurrence in 
thrombosis are unprovoked VTE, thrombophillia, 
primary DVT, shorter episode of anticoagulation 
22,24(up to 6 months), and elderly . Persistent right 
ventricular dysfunction at hospital discharge from 
first episode of PE is also associated with right 
26ventricular dysfunction . Nomogram for predicting 
recurrency in unprovoked VTE has been developed 
by scoring sex, location of VTE, and d-Dimer 
28results .
SUMMARY
Physicians should aware of pulmonary 
embolism. Diagnosing PE is not always easy. 
Patients with unexplained dyspneu, tachycardia, 
hemoptisis, with or without deep vein thrombosis 
should be assessed probability of PE with clinical 
probability test developed by Wells. Those with 
high and moderate probability should be initiated 
treatment while waiting further test. Higher d-dimer 
value directs to chest x ray and multidetector chest 
CT. If PE was detected by imaging, anticoagulation 
is continued for up to 6 month. Unprovoked VTE 
needs lifelong anticoagulation.
REFERENCES
1. Konstantinides S. Acute Pulmonary 
Embolism. N Engl J Med 2008;359:2804-
13.
2. G o l d h a b e r  S . Z .  P u l m o n a r y  
thromboembolism in Kasper D.L., 
Braunwald E., Fauci A.S.,Harrison's 
Principles of Internal Medicine (16th ed.). 
New York, NY: McGraw-Hill. 2005 pp. 
1561–65. 
3. Tapson V.F. Acute Pulmonary Embolism. N 
Engl J Med 2008;358:1037-52. 
4. Leizorovicz A, Turpie A.G.G., Cohen A.T., 
Wong L., Yoo M.C., Dans A. Epidemiology 
of venous thromboembolism in Asian patients 
undergoing major orthopedic surgery without 
thromboprophylaxis: the SMART Study. J 
Thromb Haemost 2005; 3:28-34.
5. Torbicki A, Perrier A, Konstantinides S. 
Guidelines on the diagnosis and management 
of acute pulmonary embolism: the Task Force 
for the Diagnosis and Management of Acute 
Pulmonary Embolism of the European Society 
of Cardiology (ESC). Eur. Heart J. 
2008;29:(18): 2276–315.
6. Goldhaber S.Z., Elliott C.G. Acute Pulmonary 
E m b o l i s m :  P a r t  I  E p i d e m i o l o g y,  
Pathophysiology, and Diagnosis. Circulation. 
2003;108:2726-2729
7. Goldhaber S.Z. and Elliott C.G. Acute 
Pulmonary Embolism: Part II: Risk 
Stratification, Treatment, and Prevention. 
Circulation 2003;108;2834-2838
8. Becattini C., Vedovati M.C., Agnelli G. 
Prognostic Value of Troponins in Acute 
Pulmonary Embolism A Meta-Analysis. 
Circulation. 2007;116:427-433
9. Wells P.S.., Ginsberg J.S., Anderson D.R. Use 
of a clinical model for safe management of 
patients with suspected pulmonary embolism. 
Ann Intern Med 1998;129:997- 1005.
10. Wells P.S., Anderson D.R., Rodger M. 
Excluding pulmonary embolism at the bedside 
without diagnostic imaging: management of 
patients with suspected pulmonary embolism 
presenting to the emergency department by 
using a simple clinical model and D-dimer. 
Ann Intern Med: 2001;1:35:98-107.
D-Dimer Testing to Determine 
the Duration of Anticoagulation Therapy. N 
Engl J Med 2006;355:1780-9.
11. Wells P.S., Anderson D.R., Rodger M. 
Derivation of a simple clinical model to 
categorize patients' probability of pulmonary 
embolism: increasing the model's utility with 
the SimpliRED D-dimer. Thromb Haemost 
2000;83:41717-20.
The Evaluation of 
Suspected Pulmonary Embolism N Engl J 
Med 2003;349:1247-56
14. Lee A.Y., Levine M.N., Baker R.I., Bowden C, 
Kakkar A.K. , Prins M, Rickles F.R., Julian 
J.A., Haley S, Kovacs M.J., Gent M. Low-
molecular-weight heparin versus a coumarin 
for the prevention of recurrent venous 
12. Fedullo, P.F.; Tapson V.F.
. 
13. Palareti G.,Cosmi B., Legnani C, Tosetto A, 
Brusi C. ,Iorio A. for the PROLONG 
Investigators. 
35
Acute Pulmonary EmbolismVolume 1, Number 1, Juli 2011
Acta Interna - The Journal of Internal Medicine
thromboembolism in patients with cancer. N 
Engl J Med 2003; 349 (2): 146–53.
Dabigatran versus 
Warfarin in the Treatment of Acute Venous 
Thromboembol ism.  
15. Schulman S, Kearon C, Kakkar A.K., 
Mismetti, Schellong S, Eriksson H for the RE-
COVER Study Group. 
N Engl  J  Med  
2009;361:2342-52.
16. Kucher N, Rossi E,De Rosa M, Goldhaber 
S .Z .Mass ive  Pu lmonary  Embol i sm 
Circulation 2006;113:577-582
17. Wan S., Quinlan D.J., Agnelli G., Eikelboom 
J.W. Thrombolysis Compared With Heparin 
for the Initial Treatment of Pulmonary 
Embolism A Meta-Analysis  of  the 
Randomized Controlled Trials. Circulation. 
2004;110:744-749.
18. Warkentin T.E., Greinacher A., Koster A., 
Lincoff A.M. Treatment and prevention of 
heparin-induced thrombocytopenia: American 
College of Chest Physicians Evidence-Based 
Clinical Practice Guidelines (8th edition). 
Chest 2008;133:Suppl:340S-380S.
19. Fedullo P.F. Auger W.R, Kerr K.M., Rubin L.J. 
Chronic Thromboembolic Pulmonary 
Hypertension. N Engl J Med 2001;345:1465-
1472.
20. G i b s o n  N . S . ,  S o h n e  M . ,  G e r d e s ,  
V.E.A.,Nijkeuter M.,Buller H.R. The 
Importance of  Cl inical  Probabi l i ty  
Assessment in Interpreting a Normal d-Dimer 
in Patients with Suspected Pulmonary 
Embolism. Chest 2008:134:789-793.
21. Eichinger S., Weltermann A., Minar E., Stain 
M., Scho'nauer V.,Schneider B. Symptomatic 
Pulmonary Embolism and the Risk of 
Recurrent Venous Thromboembolism. Arch 
Intern Med 2004:164:92-96
22. Prandoni P.,  Noventa F., Ghirarduzz A., Pengo 
V., Bernard E. The Risk of Recurrent Venous 
Thromboembolism after Discontinuing 
Anticoagulation in Patients with Acute 
Proximal Deep Vein Thrombosis or 
Pulmonary Embolism. A Prospective Cohort 
Study in 1,626 Patients.Haematologica 2007; 
92:199-205.
23. Mismetti P.,Quenet S., Levine M. Enoxaparin 
in the Treatment of Deep Vein Thrombosis 
With or Without Pulmonary Embolism An 
Individual Patient Data Meta-analysis Chest 
2005; 128:2203–2210.
24. Nijkeuter M., So¨hne M, Tick L.W. The Natural 
Course of Hemodynamically Stable 
Pulmonary Embolism: Clinical Outcome and 
Risk Factors in a Large Prospective Cohort 
Study. Chest 2007; 131:517–523.
25. Becattini C.,Agnelli G.,Pesavento R. 
Incidence of Chronic Thromboembolic 
Pulmonary Hypertension after a First Episode 
o f  P u l m o n a r y  E m b o l i s m .  C h e s t  
2006;130:172-175
26. Grifoni S., Vanni S.,Magazzini S.
28. Eichinger S.,Heinze G., Jandeck L.M., Kyrle 
P.A., Risk Assessment of Recurrence in 
Patients With Unprovoked Deep Vein 
Thrombosis or Pulmonary Embolism: The 
Vienna Prediction Model Circulation 2010; 
121: 1630 - 1636.
. 
 
 Association 
of Persistent Right Ventricular Dysfunctionat 
Hospital Discharge After Acute Pulmonary
Embolism With Recurrent Thromboembolic 
Events. Arch Intern Med. 2006;166:2151-
2156
27. Quiros R., Kucher N.,Zou K.H. Clinical 
Validity of Negative Computed Tomography 
Scan in Patients with Suspected Pulmonary 
Embolisms a Systematic Review. JAMA 
2005;293:2012-2017
36
Kartika Widayati Taroeno-Hariadi S U B J E C T I N D E X
A
Acute Pulmonary Embolisms
Anemia
C
Child Pugh Score
Combination of Curcuma
Cystatin C
D
Depression
Diclofenac Sodium
E
Elderly
G
Ginger
H
Handgrip strength
HIV
I
Insulin resistance
IL-6
L
Latihan Pasrah Diri
Liver Cirrhosis
O
obese
osteoarthritis
P
Pain
S
Shrimp shell
Soybean
Synovial Fluid Leukocyte Count
V
VAS
Z
Zung Self-Rating Scale
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